近年来，针对罕见靶点突变阳性NSCLC的治疗策略持续取得重要突破，呈现药物选择不断丰富的可喜局面。其中部分靶向疗法已获批应用于临床，更多药物则正处于临床试验阶段，并在多项国际前沿研究中显示出令人鼓舞的疗效信号，为患者带来了新的生存希望。

For adults with clinically node-negative non-small cell lung cancer (NSCLC), assessment of more than one N1 nodal station is associated with increased nodal upstaging and improved survival, according ...

The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's ...

Patients should be selected for treatment based on the presence of an NRG1 gene fusion in tumor specimens. The Food and Drug Administration (FDA) has granted accelerated approval to Bizengri ® ...

In this phase 2 study, researchers explored whether fecal microbiota transplant could overcome resistance to immune checkpoint inhibition.

A retrospective study finds that more than one third of patients with stage I-IIIA non-small cell lung cancer do not undergo ...

Researchers have mapped lung cancer "neighborhoods", finding that cell metabolism is key for determining immunotherapy ...

A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...

A meta-analysis of more than 20 phase 3 trials found no clear survival differences by sex or age in metastatic NSCLC but ...

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...